Delaware General Assembly

Lieu/Substituted 5/21/25

Adopted in Lieu of original; takes status of original

SS 1 for SJR 7

5/9/25

Seigfried

Sen. Townsend
Rep. Minor-Brown

Sen. Buckson, Hansen, Pinkney, Sokola, Walsh, Wilson
Reps. Hilovsky, Osienski

DIRECTING THE STATE EMPLOYEE BENEFITS COMMITTEE AND THE SECRETARY OF HUMAN RESOURCES TO ENGAGE WITH INDEPENDENT CONSULTANTS AND OTHER SUPPLY CHAIN TACTICS FOR COST CONTAINMENT OF PRESCRIPTION DRUGS FOR STATE EMPLOYEES AND RETIREES’ INSURANCE PROGRAMS.

This Joint Resolution directs the State Employees Benefits Committee (SEBC) to utilize specific strategies and policies when interacting and contracting with Pharmacy Benefit Managers (PBM) in order to achieve lower cost pharacuetical drug benefit plans for the State. The Resolution requests the SEBC consider all of the following: 1. Drug cost transparency. 2. Adoption of a Pharmacy and Therapeutics Committee. 3. Any other supply chain tactics such as a reverse auction or transparency committee. 4. Formation of intra-state compacts with other states. 5. Paying similar prices for drugs paid by Medicare. 6. Require PBMs disclose administrative expenses for all pharmaceutical drugs. 7. Require PBMs to bid based on lowest pricing sources, not average wholesale price. 8. Require that all written agreements between the SEBC and PBMs that the SEBC is entitled to see the agreements between PBMs and pharmaceutical companies when those agreements the drug plans contracted on behalf of the SEBC. 9. Consider use of audits when the SEBC believes it should be entitled to information on the basis of transparency or clarity. The Resolution further directs the SEBC to prepare a report by December 1, 2025, to summarize any difficulties in implementing any of these policies.

N/A

N/A

Takes effect upon being signed into law

N/A

View HTML View PDF